Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing its full subsidiary status. The acquisition price was approximately 43.3 billion yen, and its impact on future performance is being examined.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7733","jir_company_name":"Olympus Corporation","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-06-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/7733-20260602-01.pdf","jir_short_summary":"Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing its full subsidiary status. The acquisition price was approximately 43.3 billion yen, and its impact on future performance is being examined.","jir_summary":"### Overview of the Acquisition\nOlympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing its full subsidiary status. BioProtect is engaged in research, development, and manufacturing of biodegradable prostate cancer balloons and rectal spacers, with an acquisition cost of approximately 43.3 billion yen. The acquisition aims to strengthen Olympus's medical business and expand globally. The impact on upcoming performance is under examination.\n\n### Future Outlook and Corporate Strategy\nThe specific impact on performance following the acquisition remains undecided, but Olympus aims to develop advanced medical devices and expand its market through this subsidiary acquisition. Detailed earnings guidance and business strategies will be disclosed separately. This project is being closely watched by investors as part of the company's growth strategy in the medical field.","jir_financial_highlights":"Acquisition Price: Approx. 43.3 billion yen (Unknown)\nNumber of Shares Acquired: 16,925,621 shares (Unknown)\nOwnership Ratio: 100% (Unknown)","jir_category":"","jir_hashtags":"#Olympus, #IRRelatedCategory, #JapanStocks","jir_key_figures":"Acquisition Price: Approx. 43.3 billion yen\nNumber of Shares Acquired: 16,925,621 shares\nOwnership Ratio: 100%","jir_meta_title":"\u3010Olympus\u3011 Completion of Medical Subsidiary Acquisition \uff5c June 2026","jir_meta_description":"Olympus has fully acquired Israel-based BioProtect Ltd., with an acquisition amount of approximately 43.3 billion yen. The impact on future performance is under examination.","jir_og_title":"\u3010Olympus\u3011Completion of BioProtect Subsidiary Acquisition \uff5c June 2026","jir_og_description":"Olympus has fully acquired BioProtect Ltd. The acquisition amount is approximately 43.3 billion yen, and expectations for future business development are high.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6918,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-56236","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n